Separately, in their guidance, NICE recommended arsenic trioxide, within its marketing authorisation, as an option for inducing remission and consolidation in acute promyelocytic leukaemia (characterised by presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults with untreated, low-to-intermediate risk disease (defined as a white blood cell count of 10x103 per microlitre or less), when given with all-trans-retinoic acid (ATRA), or in relapsed or refractory disease, after a retinoid and chemotherapy.